COMPUGROUP MEDICAL SE & CO. KGAA CompuGroup Medical announces medium-term targets for EBITDA-margin for the first time and confirms 2021 guidance

Directive transparence : information réglementée

14/09/2021 16:47

DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous
CompuGroup Medical announces medium-term targets for EBITDA-margin for the first time and confirms 2021 guidance

14.09.2021 / 16:47
The issuer is solely responsible for the content of this announcement.

  • Adjusted EBITDA margin expected to increase to approximately 25 % in 2023 and to approximately 27 % in 2025
  • Organic revenue growth year-on-year of 5 % and more per year expected for the years 2021 through 2025
  • Annual guidance for 2021 confirmed
  • Digitization in the healthcare sector accelerates growth

Koblenz. CompuGroup Medical SE & Co. KGaA, one of the leading e-health providers in the world, announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 % and more per year from 2021 through 2025 had been published previously. In addition, the Managing Directors have now also adopted targets for the medium-term increase in adjusted EBITDA margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and to approximately 27 % in 2025. Further information on medium-term targets will be presented at the virtual Capital Markets Day tomorrow.

In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of EUR 1 billion and EUR 1.04 billion as well as adjusted EBITDA between EUR 210 million and EUR 230 million.

Digital transformation in healthcare accelerates growth

"Digitization is finally happening in healthcare, reinforced by the pandemic. Our customers' world is transforming rapidly. CompuGroup Medical is ideally positioned to support doctors, pharmacies, hospitals and other healthcare professionals on their path towards digitization", says CEO Dr. Dirk Wössner. "Governments across Europe have realized the need to digitize and modernize the healthcare space, and the transformation is gaining speed. We are ready to capture this fantastic opportunity. Organic growth has already accelerated in the first half of this year, and we confirm our ambition to achieve an organic year-on-year revenue growth of 5 % and more per year from 2021 through 2025."

CFO Michael Rauch adds: "This year we have significantly stepped up our investments to accelerate our organic growth. At the same time, we are targeting a clear path towards increasing profitability post the investment phase we announced in December 2020. We expect to be back at former levels of profitability with an adjusted EBITDA margin of approximately 25 % in 2023 and to increase the level even further going forward with a target margin of approximately 27 % by 2025."

Further information on the virtual Capital Markets Day 2021 will be available for download on the company website www.cgm.com/ir.

Forward-Looking Statements
This release contains "forward-looking statements". Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's (CompuGroup Medical) current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the opinions expressed in this release or the actual occurrence of the forecast developments is expressly excluded.

About CompuGroup Medical SE & Co. KGaA
CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists, and other healthcare professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. Approximately 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

Contact for media representatives:
Michael Franz
Head of Brand Communication
P +49 (0) 261 8000-6100
F +49 (0) 261 8000-3100
E-mail: press@cgm.com

Contact for analysts and investors:
Claudia Thomé
Corporate Vice President Investor Relations
P +49 (0) 261 8000-7030
F +49 (0) 261 8000-3200
E-mail: claudia.thome@cgm.com

14.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Phone: +49 (0)261 8000 7030
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1233339

End of News DGAP News Service

1233339  14.09.2021